RxDoctor Payments DataLook up a doctor →

Kavita Sharma, MD

Advanced Heart Failure and Transplant Cardiology · Baltimore, MDNPI 1689870305

Payments from drug & device makers

$1,460,385in general payments, 2019–2025

Across 494 payments — averaging $2956.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$733K
  • Astrazeneca UK Limited$258K
  • Novo Nordisk AS$184K
  • Bayer$112K
  • Pfizer$86K
  • Medtronic$49K
  • plus $38K from 9 others
$9,976in research payments, 2019–2025

Across 4 payments — averaging $2494.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$6K
  • Novo Nordisk AS$2K
  • Bayer$900
  • Novo Nordisk$750

What the payments were for

  • Consulting fees$52,14882%
  • Speaking & faculty fees$8,65614%
  • Travel & lodging$1,5402%
  • Food & beverage$1,0872%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$72,887
Medicare patients
256
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$787,400
EntrestoSacubitril/Valsartan60$95,021
FarxigaDapagliflozin Propanediol66$94,316
JardianceEmpagliflozin43$73,432
EliquisApixaban23$32,672
OzempicSemaglutide11$10,027
Eplerenone11$1,273
Spironolactone83$1,103
Metoprolol Succinate38$969
Torsemide30$889
Atorvastatin Calcium23$741
Potassium Chloride17$526
Furosemide32$383
Amiodarone Hcl13$365
Losartan Potassium26$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$86,046$820,07235 claims
NovartisEntresto$732,507$95,02160 claims
AstraZenecaFarxiga$4,296$94,31666 claims
Novo NordiskOzempic$2,250$10,02711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →